Staphylococcus aureus nasal colonisation in HIV-infected individuals in Botswana

Fischer RSB, MPH¹; Reid MJA, MD MA^{2,3,4}; Mannathoko N, PhD⁴; Brown EL, PhD¹; Steenhoff AP, MBBS^{2,3,5,6}

Background

- Staphylococcus aureus, an opportunistic pathogen, is a major cause of morbidity & mortality worldwide, including Africa & a leading cause of bacteremia in southern Botswana.
- · Individuals with HIV are: at high risk of staphylococcal infection; more likely to suffer severe clinical disease forms, i.e. pneumonia & bacteremia; their diseases are often life-threatening & they may fail to respond to treatment.
- S. aureus nasal colonisation is a primary risk factor for disease. Determining those at highest risk of colonisation is critical for identifying those at greatest risk of disease.
- Despite the huge burden of HIV disease in southern Africa, data describing the prevalence of S. aureus nasal carriage in this part of the world, especially in HIV-infected individuals is sparse.

Objectives

To describe the following in healthy HIV-infected individuals in & around Gaborone:

- The prevalence of asymptomatic S. aureus nasal carriage
- The proportion of colonizing S. aureus that is resistant to methicillin
- Risk factors for S. aureus carriage.

Methods

- In this cross-sectional study S. aureus carriage was investigated by collecting 2 nasal swabs, 4 weeks apart, from 418 HIV-positive outpatients attending Princess Marina Hospital (PMH) & Bamalette Lutheran Hospital (BLH) from March to June, 2013.
- Carriers were individuals with at least one swab that tested positive for S. aureus by standard microbiologic culture techniques*. Oxacillin E-test was used to determine methicillin resistance (MRSA) & susceptibility (MSSA).

*Microbiologic testing was conducted at the National Health Laboratory in Gaborone & the UT School of Public Health in Houston, Texas.

Results

- S. aureus was detected in 37.8% of study participants, of whom 49% were intermittently & 51% were persistently colonised (S. aureus identified in either one or both swabs, respectively).
- · Carriage was highest in younger participants & females: sharing of personal hygiene (i.e. bath towels, soap & deodorant) was the leading risk factor for carriage.
- Younger individuals, particularly children (<18 yrs) (PR 2.43, p=0.003) & those who accessed care at BLH (PR 2.19, p=0.005), in households with children (PR 1.36, p=0.06) or had elevated viral load (>399 copies/ml) (PR 1.88, P=0.019) were more likely to be persistent carriers.
- All children with <36% CD4 carried S. aureus (p=0.048) whereas % CD4 was higher in children who were non-carriers (p= 0.017)
- Carriage of MRSA was identified in 3.11%, but there was no 'persistent' MRSA carriage.
- MRSA carriers were more likely to be younger, especially <18 yrs (PR 1.88, p<0.001), have eczema (PR 5.72, p=0.001), asthma (PR 3.75, p=0.037), or a history of tuberculosis (PR 3.08, p=0.045).
- MRSA was more common than MSSA in patients who had a history of tuberculosis (PR 3.26, p=0.030) or pneumonia (PR 3.60, p=0.029).
- MRSA was not significantly associated with viral load or CD4 count but was more prevalent in participants on 3rd line antiretrovirals (PR 4.52, p=0.08) or with detectable viremia (PR 1.67, p=0.052).

Conclusions

- Younger individuals & women with HIV, as well as those attending healthcare at BLH or who live in larger households, constitute high-risk groups for S. aureus nasal carriage.
- Individuals with persistent viremia or who live with children are most likely to be persistent carriers.
- Children with HIV, especially those with a lower %CD4 cells are at a significantly increased risk of carriage.
- Children & patients with comorbid diseases or a history of respiratory disease constitute major risk groups for MRSA colonisation.
- Being a patient at BLH compared to PMH was a risk factor for S. aureus colonisation which requires further investigation.

Table 1. Characteristics of Study Population			Table 2. Risk Factors for S. aureus Nasal Carriage			The south and succession also also dealers the successo
Gender	Male	116 (27.75%)		Prevalence Ratio [†]		The authors graciously acknowledge the nurses,
	Female	302 (72.25%)		(95% CI)	n-value	administrators & other staff of PMH & BLH,
Viral Load (copies/ml)	<=399	378 (91.97%)	Shares Personal Hygiene Item(s)	1.80 (1.15, 2.83)	0.010	especially those in IDCC, MCH clinics & the
	>399	33 (8.03%)		1.00 (1.15, 2.05)	0.010	National Health Laboratories, without whom this
CD4 Cell Count (cells/ml)	>=500	205 (49.88%)	Female	1.79 (1.02, 3.16)	0.043	research would not have been possible
	200-499	181 (44.04%)	Attends Care at BLH	1.69 (1.19, 2.40)	0.004	References
	<200	25 (6.08%)	Household Size ≥4	1.46 (1.01, 2.11)	0.043	Boyce, J. M. 1998. "Are the Epidemiology and Microbiology of Methicillin-Resistant Staphylococcus Aureus Changing?
HAART	1st Line	309 (74.82%)	Months since Last Clinical Visit [¥]	1.02 (1.004, 1.03)	0.014	JAMA: The Journal of the American Medical Association 279 (8) (February 25): 623–624.
	2nd Line	80 (19.37%)	On ARV Line 1, 2 or 3	0.56 (0.32, 1.005)	0.052*	MRSA Bacteraemia in an HIV-infected Cohort in the HAART Era." HIV Medicine 9 (10) (November): 858–62.
	3rd Line	13 (3.15%)	Use of Asthma Inhaler	6.53 (3.34, 12.80)	<0.001*	Truong, Hong, Samir S Shah, Jonathan Ludmir, Ephraim O Twananana, Margaret Bafana, Sarah M Wood, Howard Moffat, and Andrew P Steenhoff. 2011. "Staphylococcus Aureus Skin and Soft Tissue Infections at a Tertiary Hospital in
	Custom Line	3 (0.73%)	*Each Prevalence Ratio (PR) is adjusted for all other variables in this table and age and years living with HIV; *Contains a cell value 5 individuals; *Continuous variable: PR should be interpreted as the increase in prevalence per month since last clinical visit			Botswana." South African Medical Journal 101 (6) (June): 413–6.
	Not on HAART	8 (1.94%)				Wood, Sarah M, Samir S Shah, Margaret Bafana, Adam J Ratner, Peter a Meaney, Kolaatamo C S Malefho, and Andrew P Steenhoff. 2009. "Epidemiology of Methicillin-resistant Staphylococcus Aureus Bacteremia in Gaborone, Botswana: Infection Control and Hospital Epidemiology 30 (8) (August): 782–5.

¹Center for Infectious Diseases, The University of Texas Health Science Center School of Public Health; ²Botswana-UPenn Partnership, Gaborone, Botswana;³Department of Medicine, Division of Infectious Diseases, University of Pennsylvania;⁴Univesity of Botswana, Faculty of Medicine; ⁵Center for AIDS Research, University of Pennsylvania; ⁶Department of Pediatrics, Division of Infectious Diseases, The Children's Hospital of Philadelphia













